Lenalidomide

MM combination therapy: 25 mg once daily orally on Days 1 to 21 of repeated 28-day cycles.. MM maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1 to 28 of repeated 28-day cycles. MDS: 10 mg once daily.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Pregnancy ( Boxed Warning, 4.1, 5.1, 8.1 ). Demonstrated severe hypersensitivity to lenalidomide. 4.1 Pregnancy Lenalidomide capsules can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant.

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Increased Mortality: serious and fatal cardiac adverse reactions occurred in patients with CLL treated with lenalidomide capsules. Second Primary Malignancies (SPM): Higher incidences of SPM were observed in controlled trials of patients with MM receiving lenalidomide capsules. Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue. Hepatotoxicity: Hepatic failure including fatalities; monitor liver function. Stop lenalidomide capsules and evaluate if hepatotoxicity is suspected.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following clinically significant adverse reactions are described in detail in other sections of the prescribing information: Embryo-Fetal Toxicity Hematologic Toxicity Venous and Arterial Thromboembolism Increased Mortality in Patients with CLL Second Primary Malignancies Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone Hepatotoxicity Severe Cutaneous…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

58 products from 23 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 58 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Storage Store at 20°C to 25°C (68°F to 77°F);

Storage information from the U.S. FDA-approved label.